Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

By G. Andriole, E. Crawford, R. Grubb, S. Buys, D. Chia, T. Church, M. Fouad, C. Isaacs, P. Kvale, D. Reding and 14 more. Journal of the National Cancer Institute, 2012

1,116 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/d4435292f076384d1a76f39fd100c8b369cf3756

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. R. Siegel
2. A. Jemal
3. Elizabeth E. Ward
4. Lindsey A. Torre
5. Peter L. Choyke
6. Ronald M. Summers
7. Shijun Wang
8. K. Miller

In Pulmonary and Respiratory Medicine

1. A. Jemal
2. Hans Lilja
3. Ronald M. Summers
4. Elizabeth E. Ward
5. R. Siegel
6. Shijun Wang

Citations in the corpus

• Global Cancer Incidence and Mortality Rates and Trends—An Update (2015, methodology): “trial with a different study design did not (46, 47).”
• Computer Aided-Diagnosis of Prostate Cancer on Multiparametric MRI: A Technical Review of Current Research (2014, result): “However, other large studies found conflicting results, reporting that PSA screening had no significant effect on PCa death rate [7, 8].”
• “A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer” (2019, result): “Despite several other components of this study may explain the PLCO null result, including large control group contamination, the short screening period may have contributed [23,24].”
• Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. (2014, result): “1016/S0140-6736(14)60525-0 [2] Andriole GL, Crawford ED, Grubb III RL, et al.”